Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
Full name:
Authorised dose form:
Legal status of supply:
Domain:
Resource status:
Product classification:
Document Details
Generated Narrative: Bundle TEST PURPOSES ONLY - lumeblue
Language: en
Profile: Bundle - ePI
Final Document at 2022-02-16 13:28:17+0000 by Organization ACME industry for Bundle: identifier = http://ema.europa.eu/identifier#None; type = document; timestamp = 2023-06-27 10:09:22+0000
Document Subject
Generated Narrative: MedicinalProductDefinition mp5a0e77a26a98f2eac352c48d66309743
identifier: http://ema.europa.eu/identifier
/EU/1/20/1470/001
type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Lumeblue 25 mg prolonged-release tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en
Document Content
Generated Narrative: Composition composition-en-5a0e77a26a98f2eac352c48d66309743
Language: en
Profile: Composition (ePI)
identifier: http://ema.europa.eu/identifier
/EU/1/20/1470/001
status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - lumeblue
Mode | Time |
Official | 2022-02-16 13:28:17+0000 |
What is in this leaflet
Lumeblue contains methylthioninium chloride (also known as methylene blue). This medicine is a blue dye.
This medicineis used in adults to temporarily stain the colon (large bowel) before colonoscopy, in which a flexible instrument is inserted into the rectum to view inside the bowel. The staining allows the doctor to see the lining of the colon more clearly and improves the detection of abnormalities.
Do not take Lumeblue
Warnings and precautions
Talk to your doctor or pharmacist before taking this medicine:
Other medicines and Lumeblue Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.
Other medicines and Lumeblue taken together may affect how they each work or are processed and removed from the body.
In addition to antidepressants and the other medicines for psychiatric illness mentioned under Warnings and Precautions , you should tell your doctor before you take this medicine if you are also taking or have recently been given:
Pregnancy and breast-feeding
If you are pregnant, think you may be pregnant or are planning to have a baby, do not use Lumeblue as it is not known whether this medicine can harm your unborn baby. If you are breast-feeding, ask your doctor or pharmacist for advice before taking this medicine.
Your doctor may decide that you do not need to take this medicine if you require a colonoscopy whilst breast-feeding.
Driving and using machines It is unlikely that taking Lumeblue will affect your ability to drive or use machines. However if you experience any side effects that could impair your ability to drive or use machines safely, such as migraine, feeling dizzy, or disturbance to your vision, then you should not drive or use machines until you feel better.
Lumeblue contains soya lecithin If you are allergic to peanut or soya, do not take this medicine.
Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.
The medicine is supplied as tablets. These must be swallowed whole because they have a special coating to make sure that they pass through your stomach and only break up in your intestines to release the methylthioninium chloride that stains the colon blue. You must not crush or chew them.
You will be given a pack containing 8 tablets (a total of 200 mg methylthioninium chloride). These must all be taken over a period of 2 hours, the night before your colonoscopy. Your doctor will explain how you should take the tablets, which are normally taken together with a bowel cleansing preparation (a medicine to clear out your colon).
Take the tablets as instructed by your doctor.
Typical instructions are:
After drinking at least 1 litre of the bowel cleansing preparation (or water) take the first dose of 3 tablets.
Wait 1 hour then take the second dose of 3 tablets.
Wait another hour, then take the final dose of 2 tablets.
If you take more Lumeblue than you should The box contains one complete dose of Lumeblue. Therefore you cannot take more Lumeblue than you should. However, if you take more tablets than you should, you might get some of the side effects listed in section 4. If you think you have taken more of this medicine than you should, tell your doctor or nurse as soon as possible.
If you notice any of the following symptoms you should tell your doctor straight away:
An increase in methaemoglobin (an abnormal form of haemoglobin in the blood);
High blood pressure.
If you forget to take one or more of the doses of Lumeblue Do not take a double dose to make up for a forgotten tablets, take the next dose of tablets according to the bowel cleansing schedule given to you by your doctor, it may be helpful to set an alarm to remind you when to take the medicine.
If you stop taking Lumeblue At your colonoscopy, tell your doctor that you did not take all the tablets.
If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
The following side effects are common, but tell your doctor or nurse if you are worried about any side effect you get:
Very common (may affect more than 1 in 10 people)
Common (may affect up to 1 in 10 people)
Uncommon (may affect up to 1 in 100 people)
Reporting of side effects If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system. By reporting side effects you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.
This medicine does not require any special storage conditions.
Do not use this medicine if the pack is damaged or shows signs of tampering.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Lumeblue contains
The active substance is methylthioninium chloride. Each prolonged-release tablet contains 25 mg methylthioninium chloride.
Tablet core: stearic acid 50 (E570), soya lecithin (E322) see section 2 under Lumeblue contains soya lecithin , microcrystalline cellulose (E460), hypromellose 2208 (E464), mannitol (E421), talc (E553b), silica colloidal anhydrous (E551), magnesium stearate (E470b)
What Lumeblue looks like and contents of the pack Lumeblue prolonged-release tablets are off-white to light blue, round, biconvex, enteric-coated tablets. The prolonged-release tablets are provided in blister packs containing 8 tablets.
Marketing Authorisation Holder Alfasigma S.p.A. Via Ragazzi del 99, n. 5 40133 Bologna Italy +39 0516489info.it@alfasigma.com
Manufacturer Cosmo S.p.A Via C. Colombo, 1 20045, Lainate Milan,
Italy
This leaflet was last revised in
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency web site:
Entry 1 - fullUrl = Composition/composition-en-5a0e77a26a98f2eac352c48d66309743
Resource Composition:
Generated Narrative: Composition composition-en-5a0e77a26a98f2eac352c48d66309743
Language: en
Profile: Composition (ePI)
identifier:
http://ema.europa.eu/identifier
/EU/1/20/1470/001status: Final
type: Package Leaflet
category: Raw
date: 2022-02-16 13:28:17+0000
author: Organization ACME industry
title: TEST PURPOSES ONLY - lumeblue
Attesters
Mode Time Official 2022-02-16 13:28:17+0000
Entry 2 - fullUrl = MedicinalProductDefinition/mp5a0e77a26a98f2eac352c48d66309743
Resource MedicinalProductDefinition:
Generated Narrative: MedicinalProductDefinition mp5a0e77a26a98f2eac352c48d66309743
identifier:
http://ema.europa.eu/identifier
/EU/1/20/1470/001type: Medicinal Product
domain: Human use
status: active
legalStatusOfSupply: Medicinal product subject to medical prescription
name
productName: Lumeblue 25 mg prolonged-release tablets
type: Full name
part
part: nan
type: Invented name part
part
part: nan
type: Scientific name part
part
part: nan
type: Strength part
part
part: nan
type: Pharmaceutical dose form part
Usages
Country Jurisdiction Language EU EU en